Symbols / RNA
RNA Chart
About
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy; Delpacibart etedesiran which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; and Delpacibart braxlosiran that is in Phase 1/2 development stage for the treatment of facioscapulohumeral muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 11.24B |
| Enterprise Value | 9.64B | Income | -684.63M | Sales | 18.75M |
| Book/sh | 11.17 | Cash/sh | 10.94 | Dividend Yield | — |
| Payout | 0.00% | Employees | 511 | IPO | — |
| P/E | — | Forward P/E | -19.24 | PEG | — |
| P/S | 599.22 | P/B | 6.51 | P/C | — |
| EV/EBITDA | -12.99 | EV/Sales | 513.97 | Quick Ratio | 8.75 |
| Current Ratio | 9.20 | Debt/Eq | 2.92 | LT Debt/Eq | — |
| EPS (ttm) | -4.19 | EPS next Y | -3.78 | EPS Growth | — |
| Revenue Growth | -71.10% | Earnings | 2026-05-11 | ROA | -26.47% |
| ROE | -43.98% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -295.90% | Profit Margin | 0.00% | Shs Outstand | 154.48M |
| Shs Float | 131.57M | Short Float | 5.70% | Short Ratio | 5.36 |
| Short Interest | — | 52W High | 73.06 | 52W Low | 21.51 |
| Beta | 0.93 | Avg Volume | 2.23M | Volume | 4.17M |
| Target Price | $74.64 | Recom | Hold | Prev Close | $72.75 |
| Price | $72.75 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$74.64
Mean price target
2. Current target
$72.75
Latest analyst target
3. DCF / Fair value
$-39.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$72.75
Low
$72.00
High
$96.00
Mean
$74.64
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-11 | main | Chardan Capital | Neutral → Neutral | $72 |
| 2025-10-29 | down | TD Cowen | Buy → Hold | $74 |
| 2025-10-28 | down | Chardan Capital | Buy → Neutral | $72 |
| 2025-10-28 | down | RBC Capital | Outperform → Sector Perform | $72 |
| 2025-10-27 | down | Citigroup | Buy → Neutral | $72 |
| 2025-10-27 | down | Leerink Partners | Outperform → Market Perform | $72 |
| 2025-10-27 | down | Raymond James | Strong Buy → Market Perform | — |
| 2025-10-27 | down | Bernstein | Outperform → Market Perform | $72 |
| 2025-10-27 | down | Needham | Buy → Hold | $65 |
| 2025-10-27 | down | HC Wainwright & Co. | Buy → Neutral | $72 |
| 2025-09-22 | main | Evercore ISI Group | Outperform → Outperform | $65 |
| 2025-09-17 | init | Roth Capital | — → Buy | $62 |
| 2025-09-15 | main | B of A Securities | Buy → Buy | $65 |
| 2025-09-12 | main | HC Wainwright & Co. | Buy → Buy | $87 |
| 2025-09-10 | main | Needham | Buy → Buy | $65 |
| 2025-09-10 | main | Chardan Capital | Buy → Buy | $75 |
| 2025-08-08 | main | Wells Fargo | Overweight → Overweight | $75 |
| 2025-08-08 | main | Barclays | Overweight → Overweight | $62 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $75 |
| 2025-06-27 | reit | Cantor Fitzgerald | Overweight → Overweight | $96 |
News
RSS: Latest RNA news- Biotech delays key vote as Atrium stock distribution, Novartis merger approach - Stock Titan Mon, 23 Feb 2026 13
- Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring Growth Potential Amidst 434% Revenue Surge - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- Avidity Biosciences (RNA) Posts FY 2025 US$237 Million Loss Challenging Bullish Growth Narratives - simplywall.st Wed, 25 Feb 2026 00
- RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders - Business Wire ue, 28 Oct 2025 07
- Avidity Biosciences Advances Toward Novartis Merger Completion - TipRanks Mon, 23 Feb 2026 14
- Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating - Yahoo Finance Sat, 13 Sep 2025 07
- Avidity Biosciences, Inc. SEC 10-K Report - TradingView Mon, 23 Feb 2026 21
- Avidity Biosciences CSO sells $473k in RNA stock - Investing.com Fri, 23 Jan 2026 08
- Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - PR Newswire hu, 11 Sep 2025 07
- RNA splicing pioneer Olga Anczukow joins Akari cancer drug board - Stock Titan Mon, 23 Feb 2026 13
- Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring a 36.85% Potential Upside in Innovative RNA Therapeutics - DirectorsTalk Interviews Mon, 13 Oct 2025 07
- Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger - Yahoo Finance Sun, 02 Nov 2025 07
- Avidity Biosciences director Wilson sells $1.4m in RNA stock - Investing.com ue, 09 Sep 2025 07
- Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring Growth Potential In RNA Therapeutics - DirectorsTalk Interviews Mon, 16 Feb 2026 08
- Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights - PR Newswire Mon, 10 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1758 | 127367 | — | Sale at price 72.45 per share. | LEVIN ARTHUR A. | Director | — | 2026-01-21 00:00:00 | D |
| 1 | 4542 | 329068 | — | Sale at price 72.45 per share. | MACLEAN MICHAEL F. | Chief Financial Officer | — | 2026-01-21 00:00:00 | D |
| 2 | 14387 | 1042338 | — | Sale at price 72.45 per share. | BOYCE SARAH | Chief Executive Officer | — | 2026-01-21 00:00:00 | D |
| 3 | 4895 | 354643 | — | Sale at price 72.45 per share. | HUGHES STEVEN GEORGE | Officer | — | 2026-01-21 00:00:00 | D |
| 4 | 6534 | 473388 | — | Sale at price 72.45 per share. | FLANAGAN WILLIAM MICHAEL | Officer | — | 2026-01-21 00:00:00 | D |
| 5 | 2929 | 212206 | — | Sale at price 72.45 per share. | MCCARTHY TERESA | Officer | — | 2026-01-21 00:00:00 | D |
| 6 | 1974 | 142582 | — | Sale at price 72.23 per share. | MACLEAN MICHAEL F. | Chief Financial Officer | — | 2026-01-07 00:00:00 | D |
| 7 | 2374 | 171474 | — | Sale at price 72.23 per share. | MORIARTY JOHN B | Officer | — | 2026-01-07 00:00:00 | D |
| 8 | 8576 | 619444 | — | Sale at price 72.23 per share. | BOYCE SARAH | Chief Executive Officer | — | 2026-01-07 00:00:00 | D |
| 9 | 2373 | 171402 | — | Sale at price 72.23 per share. | HUGHES STEVEN GEORGE | Officer | — | 2026-01-07 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -376.16M | -233.50M | -177.53M | -117.41M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -322.30M | -212.22M | -174.00M | -118.01M |
| ReconciledDepreciation | 2.78M | 2.10M | 1.39M | 639.00K |
| EBITDA | -376.16M | -233.50M | -177.53M | -117.41M |
| EBIT | -378.94M | -235.60M | -178.91M | -118.05M |
| NetInterestIncome | 56.88M | 23.97M | 4.97M | 104.00K |
| InterestExpense | 0.00 | 0.00 | ||
| InterestIncome | 56.88M | 23.97M | 4.97M | 104.00K |
| NormalizedIncome | -322.30M | -212.22M | -174.00M | -118.01M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -322.30M | -212.22M | -174.00M | -118.01M |
| TotalExpenses | 389.83M | 245.16M | 188.14M | 127.38M |
| TotalOperatingIncomeAsReported | -378.94M | -235.60M | -178.91M | -118.05M |
| DilutedAverageShares | 111.58M | 73.01M | 52.16M | 20.71M |
| BasicAverageShares | 111.58M | 73.01M | 52.16M | 20.71M |
| DilutedEPS | -2.89 | -2.91 | -3.34 | -5.70 |
| BasicEPS | -2.89 | -2.91 | -3.34 | -5.70 |
| DilutedNIAvailtoComStockholders | -322.30M | -212.22M | -174.00M | -118.01M |
| NetIncomeCommonStockholders | -322.30M | -212.22M | -174.00M | -118.01M |
| NetIncome | -322.30M | -212.22M | -174.00M | -118.01M |
| NetIncomeIncludingNoncontrollingInterests | -322.30M | -212.22M | -174.00M | -118.01M |
| NetIncomeContinuousOperations | -322.30M | -212.22M | -174.00M | -118.01M |
| PretaxIncome | -322.30M | -212.22M | -174.00M | -118.01M |
| OtherIncomeExpense | -248.00K | -594.00K | -57.00K | -62.00K |
| OtherNonOperatingIncomeExpenses | -248.00K | -594.00K | -57.00K | -62.00K |
| NetNonOperatingInterestIncomeExpense | 56.88M | 23.97M | 4.97M | 104.00K |
| InterestExpenseNonOperating | 0.00 | 0.00 | ||
| InterestIncomeNonOperating | 56.88M | 23.97M | 4.97M | 104.00K |
| OperatingIncome | -378.94M | -235.60M | -178.91M | -118.05M |
| OperatingExpense | 389.83M | 245.16M | 188.14M | 127.38M |
| ResearchAndDevelopment | 303.59M | 190.97M | 150.40M | 101.18M |
| SellingGeneralAndAdministration | 86.24M | 54.19M | 37.73M | 26.20M |
| GeneralAndAdministrativeExpense | 86.24M | 54.19M | 37.73M | 26.20M |
| OtherGandA | 86.24M | 54.19M | 37.73M | 26.20M |
| TotalRevenue | 10.90M | 9.56M | 9.22M | 9.33M |
| OperatingRevenue | 10.90M | 9.56M | 9.22M | 9.33M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 119.89M | 79.28M | 69.77M | 47.75M |
| ShareIssued | 119.89M | 79.28M | 69.77M | 47.75M |
| TotalDebt | 6.80M | 9.85M | 10.69M | 11.73M |
| TangibleBookValue | 1.42B | 500.76M | 578.08M | 381.43M |
| InvestedCapital | 1.42B | 500.76M | 578.08M | 381.43M |
| WorkingCapital | 1.44B | 530.63M | 571.03M | 381.48M |
| NetTangibleAssets | 1.42B | 500.76M | 578.08M | 381.43M |
| CapitalLeaseObligations | 6.80M | 9.85M | 10.69M | 11.73M |
| CommonStockEquity | 1.42B | 500.76M | 578.08M | 381.43M |
| TotalCapitalization | 1.42B | 500.76M | 578.08M | 381.43M |
| TotalEquityGrossMinorityInterest | 1.42B | 500.76M | 578.08M | 381.43M |
| StockholdersEquity | 1.42B | 500.76M | 578.08M | 381.43M |
| GainsLossesNotAffectingRetainedEarnings | 2.90M | 125.00K | -2.70M | -187.00K |
| OtherEquityAdjustments | 2.90M | 125.00K | -2.70M | -187.00K |
| RetainedEarnings | -893.07M | -570.76M | -358.54M | -184.55M |
| AdditionalPaidInCapital | 2.32B | 1.07B | 939.31M | 566.16M |
| CapitalStock | 12.00K | 8.00K | 7.00K | 5.00K |
| CommonStock | 12.00K | 8.00K | 7.00K | 5.00K |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 138.94M | 127.79M | 60.73M | 46.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 40.92M | 47.11M | 8.82M | 16.49M |
| NonCurrentDeferredLiabilities | 37.96M | 40.90M | 1.24M | 6.53M |
| NonCurrentDeferredRevenue | 37.96M | 40.90M | 1.24M | 6.53M |
| LongTermDebtAndCapitalLeaseObligation | 2.96M | 6.21M | 7.58M | 9.96M |
| LongTermCapitalLeaseObligation | 2.96M | 6.21M | 7.58M | 9.96M |
| CurrentLiabilities | 98.02M | 80.68M | 51.91M | 29.66M |
| CurrentDeferredLiabilities | 20.99M | 28.36M | 5.04M | 4.86M |
| CurrentDeferredRevenue | 20.99M | 28.36M | 5.04M | 4.86M |
| CurrentDebtAndCapitalLeaseObligation | 3.84M | 3.64M | 3.10M | 1.77M |
| CurrentCapitalLeaseObligation | 3.84M | 3.64M | 3.10M | 1.77M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.66M | 14.34M | 11.19M | 8.94M |
| PayablesAndAccruedExpenses | 69.52M | 34.34M | 32.57M | 14.09M |
| CurrentAccruedExpenses | 61.06M | 25.53M | 27.93M | 11.28M |
| Payables | 8.46M | 8.81M | 4.64M | 2.81M |
| AccountsPayable | 8.46M | 8.81M | 4.64M | 2.81M |
| TotalAssets | 1.56B | 628.55M | 638.80M | 427.58M |
| TotalNonCurrentAssets | 21.61M | 17.25M | 15.86M | 16.44M |
| OtherNonCurrentAssets | 3.32M | 596.00K | 849.00K | 850.00K |
| NetPPE | 18.29M | 16.65M | 15.01M | 15.59M |
| AccumulatedDepreciation | -8.00M | -5.22M | -3.12M | -1.73M |
| GrossPPE | 26.29M | 21.87M | 18.13M | 17.32M |
| Leases | 288.00K | 288.00K | 249.00K | 249.00K |
| ConstructionInProgress | 3.96M | 0.00 | ||
| OtherProperties | 14.18M | 19.48M | 15.97M | 15.56M |
| MachineryFurnitureEquipment | 2.24M | 2.11M | 1.91M | 1.51M |
| BuildingsAndImprovements | 5.62M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.54B | 611.31M | 622.94M | 411.14M |
| OtherCurrentAssets | 12.21M | 5.60M | ||
| PrepaidAssets | 12.57M | 7.33M | 8.34M | 5.60M |
| Receivables | 28.22M | 8.62M | 3.88M | |
| AccruedInterestReceivable | 28.22M | 7.52M | 1.51M | |
| AccountsReceivable | 0.00 | 1.10M | 2.36M | |
| CashCashEquivalentsAndShortTermInvestments | 1.50B | 595.35M | 610.73M | 405.54M |
| OtherShortTermInvestments | 1.28B | 410.27M | 270.33M | 85.09M |
| CashAndCashEquivalents | 219.87M | 185.08M | 340.40M | 320.45M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -307.94M | -123.29M | -139.09M | -98.55M |
| RepaymentOfDebt | 0.00 | 0.00 | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 1.00B | 91.74M | 344.78M | 174.68M |
| CapitalExpenditure | -7.07M | -4.23M | -2.82M | -3.74M |
| InterestPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 222.66M | 185.38M | 340.65M | 320.70M |
| BeginningCashPosition | 185.38M | 340.65M | 320.70M | 321.71M |
| ChangesInCash | 37.29M | -155.27M | 19.95M | -1.01M |
| FinancingCashFlow | 1.19B | 93.86M | 346.17M | 176.32M |
| CashFlowFromContinuingFinancingActivities | 1.19B | 93.86M | 346.17M | 176.32M |
| NetOtherFinancingCharges | -11.26M | |||
| ProceedsFromStockOptionExercised | 191.81M | 2.13M | 1.39M | 1.64M |
| CashDividendsPaid | 0.00 | |||
| NetPreferredStockIssuance | 31.19M | 0.00 | 0.00 | |
| PreferredStockIssuance | 31.19M | 0.00 | 0.00 | |
| NetCommonStockIssuance | 1.00B | 91.74M | 344.78M | 174.68M |
| CommonStockIssuance | 1.00B | 91.74M | 344.78M | 174.68M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | 0.00 | ||
| LongTermDebtPayments | 0.00 | 0.00 | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -854.20M | -130.07M | -189.96M | -82.52M |
| CashFlowFromContinuingInvestingActivities | -854.20M | -130.07M | -189.96M | -82.52M |
| NetInvestmentPurchaseAndSale | -847.13M | -125.84M | -187.13M | -78.78M |
| SaleOfInvestment | 586.40M | 335.16M | 168.71M | 6.58M |
| PurchaseOfInvestment | -1.43B | -461.00M | -355.84M | -85.36M |
| NetPPEPurchaseAndSale | -7.07M | -4.23M | -2.82M | -3.74M |
| PurchaseOfPPE | -7.07M | -4.23M | -2.82M | -3.74M |
| OperatingCashFlow | -300.87M | -119.06M | -136.27M | -94.81M |
| CashFlowFromContinuingOperatingActivities | -300.87M | -119.06M | -136.27M | -94.81M |
| ChangeInWorkingCapital | -14.56M | 61.13M | 7.07M | 4.64M |
| ChangeInOtherWorkingCapital | -10.31M | 62.99M | -5.12M | -4.44M |
| ChangeInOtherCurrentLiabilities | -3.70M | -3.33M | -1.76M | -234.00K |
| ChangeInPayablesAndAccruedExpense | 24.51M | 4.91M | 20.57M | 11.83M |
| ChangeInAccruedExpense | -10.67M | 3.15M | 2.25M | 5.79M |
| ChangeInPayable | 35.18M | 1.77M | 18.32M | 6.04M |
| ChangeInAccountPayable | 35.18M | 1.77M | 18.32M | 6.04M |
| ChangeInPrepaidAssets | -25.06M | -3.44M | -6.62M | -2.51M |
| OtherNonCashItems | 3.30M | 2.98M | 2.75M | 679.00K |
| StockBasedCompensation | 51.36M | 38.22M | 27.14M | 17.06M |
| AmortizationOfSecurities | -21.45M | -11.27M | -615.00K | 179.00K |
| DepreciationAmortizationDepletion | 2.78M | 2.10M | 1.39M | 639.00K |
| DepreciationAndAmortization | 2.78M | 2.10M | 1.39M | 639.00K |
| Depreciation | 2.78M | 2.10M | 1.39M | 639.00K |
| OperatingGainsLosses | -16.00K | |||
| GainLossOnSaleOfPPE | -16.00K | |||
| NetIncomeFromContinuingOperations | -322.30M | -212.22M | -174.00M | -118.01M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RNA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|